Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

How our clients use DrugPatentWatch

Generated: April 27, 2017

DrugPatentWatch Database Preview

Imatinib mesylate - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for imatinib mesylate and what is the scope of freedom to operate?

Imatinib mesylate
is the generic ingredient in two branded drugs marketed by Novartis, Sun Pharma Global, Apotex Inc, and Teva Pharms Usa, and is included in five NDAs. There are five patents protecting this compound and two Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Imatinib mesylate has forty-six patent family members in thirty-one countries.

There are thirty-one drug master file entries for imatinib mesylate. Nine suppliers are listed for this compound.

Summary for Generic Name: imatinib mesylate

Drug Master File Entries: see list31
Suppliers / Packagers: see list9
Bulk Api Vendors: see list101
Clinical Trials: see list278
Patent Applications: see list8,900
Therapeutic Class:Antineoplastics
Formulation / Manufacturing:see details
Drug Prices:see low prices
DailyMed Link:imatinib mesylate at DailyMed

Pharmacology for Ingredient: imatinib mesylate

Drug ClassKinase Inhibitor
Mechanism of ActionProtein Kinase Inhibitors
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
imatinib mesylate
CAPSULE;ORAL021335-001May 10, 2001DISCNYesNo6,894,051*PED► SubscribeY► Subscribe
Teva Pharms Usa
imatinib mesylate
TABLET;ORAL204285-002Aug 4, 2016ABRXNoNo► Subscribe► Subscribe
imatinib mesylate
TABLET;ORAL021588-002Apr 18, 2003ABRXYesYes7,544,799*PED► SubscribeY► Subscribe
imatinib mesylate
TABLET;ORAL021588-001Apr 18, 2003ABRXYesNo6,958,335*PED► SubscribeY► Subscribe
imatinib mesylate
TABLET;ORAL021588-001Apr 18, 2003ABRXYesNo7,544,799*PED► SubscribeY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Subscribe for Complete Access

  • Formulary management
  • Obtain formulation and manufacturing information
  • Drug patents and clinical trials in dozens of countries

► Plans and Pricing

Expired Orange Book Patents

 Available with subscription

Paragraph IV Activity

 Available with subscription

Patent Maintenance

 Available with subscription

Non-Orange Book Patents

 Available with subscription

International Patents

 Available with subscription

Supplementary Protection Certificates

 Available with subscription

« Back to the Dashboard

For more information try a trial or see the database preview and plans and pricing

How our clients use DrugPatentWatch

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:

Google Plus